Cullinan Management, Inc. (CGEM)
|Net Income (ttm)||-35.08M|
|Trading Day||January 19|
|Day's Range||32.63 - 35.99|
|52-Week Range||28.00 - 37.50|
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and ...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlie...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline...
Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday.
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Nasdaq:ZLAB
- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with tran...
Cullinan Management, Inc. has filed to go public with an IPO on the NASDAQ.
Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of soli... [Read more...]
|IPO Date |
Jan 8, 2021
|Stock Exchange |
|Ticker Symbol |